Literature DB >> 21547913

Reversion of sulfenamide prodrugs in the presence of free thiol-containing proteins.

Kwame W Nti-Addae1, Jennifer S Laurence, Andria L Skinner, Valentino J Stella.   

Abstract

The purpose of this work was to study the reaction kinetics between two model sulfenamide prodrugs of linezolid, N-(phenylthio)linezolid and N-[(2-ethoxycarbonyl)ethylthio]linezolid, with free thiol-containing proteins; commercial human serum albumin (HSA); a constitutively active mutant of the protein tyrosine phosphatase PRL-1 (PRL-1-C170S-C171S), a model protein; and diluted fresh human plasma. The reaction was followed by high-performance liquid chromatography, both for the loss of prodrug and appearance of linezolid, and at different pH values with molar excess of the proteins relative to the prodrugs. Pseudo first-order kinetics was observed. Consistent with earlier findings for the reaction between similar sulfenamides and small-molecule thiols, the reaction kinetics appeared to be consistent with thiolate attack at the sulfenamide bond to release the parent drug. The proteins reacted significantly slower on a molar basis than their small-molecule counterparts. It appears that proteins such as HSA may play a role in the in vivo conversion of sulfenamide prodrugs to their parent drug.
Copyright © 2011 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21547913      PMCID: PMC3713482          DOI: 10.1002/jps.22505

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  14 in total

Review 1.  Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development.

Authors:  Zhong-Yin Zhang
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002       Impact factor: 13.820

Review 2.  Practical aspects of the ligand-binding and enzymatic properties of human serum albumin.

Authors:  Ulrich Kragh-Hansen; Victor Tuan Giam Chuang; Masaki Otagiri
Journal:  Biol Pharm Bull       Date:  2002-06       Impact factor: 2.233

3.  Plasma albumin concentration is a predictor of HbA1c among type 2 diabetic patients, independently of fasting plasma glucose and fructosamine.

Authors:  Santiago Rodríguez-Segade; Javier Rodríguez; Dolores Mayan; Felix Camiña
Journal:  Diabetes Care       Date:  2005-02       Impact factor: 19.112

4.  Kinetic analysis of the covalent binding of captopril to human serum albumin.

Authors:  R Narazaki; K Harada; A Sugii; M Otagiri
Journal:  J Pharm Sci       Date:  1997-02       Impact factor: 3.534

Review 5.  Glutathione: toxicological implications.

Authors:  D J Reed
Journal:  Annu Rev Pharmacol Toxicol       Date:  1990       Impact factor: 13.820

6.  Kinetic studies of covalent binding between N-acetyl-L-cysteine and human serum albumin through a mixed-disulfide using an N-methylpyridinium polymer-based column.

Authors:  Daisuke Harada; Makoto Anraku; Hikaru Fukuda; Shinsaku Naito; Kumiko Harada; Ayaka Suenaga; Masaki Otagiri
Journal:  Drug Metab Pharmacokinet       Date:  2004-08       Impact factor: 3.614

7.  In vitro conversion of model sulfenamide prodrugs in the presence of small molecule thiols.

Authors:  Kwame W Nti-Addae; Valentino J Stella
Journal:  J Pharm Sci       Date:  2010-10-18       Impact factor: 3.534

8.  Preparation, characterization and in vivo conversion of new water-soluble sulfenamide prodrugs of carbamazepine.

Authors:  Jeffrey N Hemenway; Kwame Nti-Addae; Victor R Guarino; Valentino J Stella
Journal:  Bioorg Med Chem Lett       Date:  2007-09-15       Impact factor: 2.823

9.  Enzyme activity of phosphatase of regenerating liver is controlled by the redox environment and its C-terminal residues.

Authors:  Andria L Skinner; Anthony A Vartia; Todd D Williams; Jennifer S Laurence
Journal:  Biochemistry       Date:  2009-05-26       Impact factor: 3.162

10.  Sulfenamides as prodrugs of NH-acidic compounds: a new prodrug option for the amide bond.

Authors:  Victor R Guarino; Veranja Karunaratne; Valentino J Stella
Journal:  Bioorg Med Chem Lett       Date:  2007-06-13       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.